Literature DB >> 29437913

Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels.

Fernando Magro1,2, Joanne Lopes3, Paula Borralho4, Susana Lopes1, Rosa Coelho1, José Cotter5, Francisca Dias de Castro5, Helena Tavares de Sousa6,7, Marta Salgado8, Patrícia Andrade1, Ana Isabel Vieira9, Pedro Figueiredo9, Paulo Caldeira10, A Sousa10, Maria A Duarte11, Filipa Ávila11, João Silva12, Joana Moleiro12, Sofia Mendes13, Sílvia Giestas13, Paula Ministro14, Paula Sousa14, Raquel Gonçalves15, Bruno Gonçalves15, Ana Oliveira16, Isadora Rosa12, Marta Rodrigues3, Cristina Chagas17, Cláudia Camila Dias18,19, Joana Afonso2,20, Karel Geboes21, Fátima Carneiro3,22.   

Abstract

OBJECTIVE: Histological remission is being increasingly acknowledged as a therapeutic endpoint in patients with UC. The work hereafter described aimed to evaluate the concordance between three histological classification systems-Geboes Score (GS), Nancy Index (NI) and RobartsHistopathologyIndex (RHI), as well as to evaluate their association with the endoscopic outcomes and the faecal calprotectin (FC) levels.
DESIGN: Biopsy samples from 377 patients with UC were blindly evaluated using GS, NI and RHI. The results were compared with the patients' Mayo Endoscopic Score and FC levels. RESULT: GS, NI and RHI have a good concordance concerning the distinction between patients in histological remission or activity. RHI was particularly close to NI, with 100% of all patients classified as being in remission with NI being identified as such with RHI and 100% of all patients classified as having activity with RHI being identified as such with NI. These scores could also predict the Mayo Endoscopic Score and the FC levels, with their sensitivity and specificity levels depending on the chosen cut-offs. Moreover, higher FC levels were statistically associated with the presence of neutrophils in the epithelium, as well as with ulceration or erosion of the intestinal mucosa.
CONCLUSIONS: GS, NI and RHI histopathological scoring systems are comparable in what concerns patients' stratification into histological remission/activity. Additionally, FC levels are increased when neutrophils are present in the epithelium and the intestinal mucosa has erosions or ulcers. The presence of neutrophils in the epithelium is, indeed, the main marker of histological activity. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  histopathology; inflammatory bowel disease; stool markers; ulcerative colitis

Mesh:

Substances:

Year:  2018        PMID: 29437913     DOI: 10.1136/gutjnl-2017-315545

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.

Authors:  Kelly C Cushing; William Tan; David H Alpers; Vikram Deshpande; Ashwin N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2019-11-07       Impact factor: 8.171

Review 2.  Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?

Authors:  Robert Battat; Parambir S Dulai; Christopher Ma; Vipul Jairath; Brian G Feagan; William J Sandborn; Reena Khanna
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-04

3.  Combined Endoscopic and Oral Fecal Microbiota Transplantation in Patients with Antibiotic-Dependent Pouchitis: Low Clinical Efficacy due to Low Donor Microbial Engraftment.

Authors:  Hans Herfarth; Edward L Barnes; Millie D Long; Kim L Isaacs; Tom Leith; Michael Silverstein; Ylaine Gerardin; Zain Kassam
Journal:  Inflamm Intest Dis       Date:  2019-03-29

4.  Inflammation of the appendix in ulcerative colitis - Does it have a predictive value?

Authors:  Fernando Magro; Maria Manuela Estevinho; Roger Feakins
Journal:  United European Gastroenterol J       Date:  2021-12-02       Impact factor: 4.623

5.  Impact of COVID-19 on Patients with Inflammatory Bowel Disease.

Authors:  Paula A Ambrose; Wendy A Goodman
Journal:  J Explor Res Pharmacol       Date:  2021-10-12

6.  Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis.

Authors:  Antonio Riva; Elizabeth H Gray; Sarah Azarian; Ane Zamalloa; Mark J W McPhail; Royce P Vincent; Roger Williams; Shilpa Chokshi; Vishal C Patel; Lindsey A Edwards
Journal:  JHEP Rep       Date:  2020-07-30

7.  Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.

Authors:  Maya Olaisen; Olav Spigset; Arnar Flatberg; Atle van Beelen Granlund; Wenche Rødseth Brede; Grethe Albrektsen; Elin Synnøve Røyset; Bodil Gilde; Arne Kristian Sandvik; Tom Christian Martinsen; Reidar Fossmark
Journal:  Aliment Pharmacol Ther       Date:  2019-03-20       Impact factor: 8.171

8.  Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.

Authors:  Fernando Magro; Susana Lopes; Marco Silva; Rosa Coelho; Francisco Portela; Diogo Branquinho; Luís Correia; Samuel Fernandes; Marília Cravo; Paulo Caldeira; Helena Tavares de Sousa; Marta Patita; Paula Lago; Jaime Ramos; Joana Afonso; Isabel Redondo; Patrícia Machado; George Philip; Joanne Lopes; Fátima Carneiro
Journal:  Therap Adv Gastroenterol       Date:  2019-08-30       Impact factor: 4.409

9.  Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease.

Authors:  Sjoukje-Marije Haisma; Henkjan J Verkade; Rene Scheenstra; Hubert P J van der Doef; Frank A J A Bodewes; Patrick F van Rheenen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-10       Impact factor: 2.839

Review 10.  Disease monitoring strategies in inflammatory bowel diseases: What do we mean by "tight control"?

Authors:  Lorant Gonczi; Talat Bessissow; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2019-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.